Prevention of simian immunodeficiency virus, SIV(sm), or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005

AIDS

Volumn 11, Issue 2, 1997, Pages 157-162

  Böttiger, Disa ^a,b   Johansson, Nils Gunnar ^b   Samuelsson, Bengt ^c   Zhang, Hong ^b   Putkonen, Per ^d   Vrang, Lotta ^b   Öberg, Bo ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDIVIR AB   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Animal model; BEA 005; HIV 2; Monkeys; Postexposure treatment; Simian immunodeficiency virus; Therapy

Indexed keywords

2',3' DIDEOXY 3' HYDROXYMETHYLCYTIDINE; ANTIVIRUS AGENT; NUCLEOSIDE ANALOG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CYTIDINE; HIV INFECTIONS; HIV-2; MACACA FASCICULARIS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

EID: 0031029005     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199702000-00004     Document Type: Article

References (24)

1. Gerberding JL: Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis 1944, 170:1410-1417.
2. Gardner MB: Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents. Antiviral Res 1991, 15:267-286.
3. Tsai C-C, Follis K E, Abo A, et al.: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995, 270:1197-1199.
4. Svansson L, Kvarnström I: Synthesis of 2′, 3′-dideoxy-3′-C-hydroxymethyl nucleosides as potential inhibitors of HIV. J Org Chem 1991, 56:2993-2997.
5. Sterzycki RZ, Martin JC, Wittman M, et al.: Synthesis and antiviral evaluation of 3′-branched nucleoside analogues. Nucleos Nucleot 1991, 10:291-294.
6. sm) as a model to evaluate antiviral compounds. Effects of 3′-azidothymidine, 3′-deoxythymidine, foscarnet and 2′,3′-dideoxycytidine. Antiviral Chem Chemother 1990, 5:299-306.
7. Lundgren B, Böttiger D, Ljungdahl-Ståhle E, et al.: Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr 1991, 4:489-498.
8. Böttiger D, Putkonen P, Öberg B: Prevention of HIV-2 and SIV by FLT in monkeys. AIDS Res Hum Retrovirus 1992, 7:1235-1238.
9. Putkonen P, Kaaya EE, Böttiger D, et al.: Clinical features and predictive markers of disease progression in cynomolgus monkeys experimentally infected with simian immunodeficiency virus. AIDS 1992, 6:257-265.
10. sm challenge in macaques infected with a chimeric SIV that expresses HIV-1 envelope. AIDS Res Hum Retrovirus 1996, 12:993-999.
11. Putkonen P, Thorstensson R, Walther E, et al.: Vaccine protection against HIV-2 infection in cynomolgus monkeys. AIDS Res Hum Retrovir 1991, 7:271-277.
12. Thorstensson K, Walther I, Putkonen P, Albert J, Biberfeld G: A capture enzyme immunoassay for detection of HIV-2/SIV antigen. J Acquir Immun Defic Syndr 1991, 374-379.
13. Ljungdahl-Ståhle E, Trojnar J, Öberg B, Wahren B: Early appearance of simian immunodeficiency virus (SIV) antigen and antibodies as variables in evaluating antiviral drugs in macaques. J Virol Methods 1992, 37:43-53.
14. McClure HM, Anderson DC, Ansari AA, Fultz PN, Klumpp SA, Shinazi RF: Nonhuman primate models for evaluation of AIDS therapy. Ann NY Acad Sci 1990: 287-298.
15. Böttiger D, Ljungdahl-Ståhle E, O̊berg B: Treatment of acute SIV infection in cynomolgus monkeys with 2′,3′-dideoxyinosine (ddl) and 2′,3′-dideoxythymidiene (d4T). Antiviral Chem Chemother 1991, 2:357-361.
16. Wyand MS: The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines. AIDS Res Hum Retrovirus 1992, 8:349-356.
17. Van Rompay KKA, Marthas ML, Ramos RA, et al.: Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother 1992, 36:2381-2386.
18. Martin LN, Murphey-Corb M, Soike KF, Davisson-Fairburn B, Baskin GB: Effects of initiation of 3′-azido-3′-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis 1993, 168:825-835.
19. Le Grand R, Clayette P, Noack O, et al.: An animal model for antilentiviral therapy: effect of zidovudine on viral load during acute infection after exposure of macaques to simian immunodeficiency virus. AIDS Res Hum Retrovirus 1994, 10:1279-1287.
20. Böttiger D, Vrang L, Öberg B: Influence of the infectious dose of simian immunodeficiency virus on the acute infection in cynomolgus monkeys and on the effect of treatment with 3′-fluorothymidine. Antiviral Chem Chemother 1992, 3:267-271.
21. Van Rompay KKA, Otsyola MG, Marthas ML, Miller CJ, McChesney MB, Pedersen NC: Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 1995, 39:125-131.
22. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
23. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection Nature 1995, 373:117-122.
24. Martin LN, Soike KF, Murphey-Corb M, et al.: Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus macaques. Antimicrob Agents Chemother 1994, 38:1277-1283.